ALLO-ASC
Phase 1Cell therapy
ALLO-ASC is one of 14 biologic programs targeting Fecal Incontinence. It is currently in Phase 1.
2
Indications
3
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Fecal Incontinence
#DrugCompanyPhaseTrials
1Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Flagyl
DDePuy Orthopaedics
Approved
Catapres
Boehringer IngelheimPhase 3
Welchol
CCosette Pharmaceuticals, Inc.
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Imodium
KKenvue Brands
Phase 2
Ramosetron
AstellasPhase 2
Viberzi
AbbViePhase 2
Psyllium
SSeoul National University Hospital
Phase 3
Botulinum Toxin a
GSKPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALLO-ASC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details